Technology | Treatment Planning | February 01, 2017

New RayStation Release to Include TomoTherapy Planning

Users will be able to accomplish all treatment planning for conventional radiotherapy and TomoTherapy from one point of control

RayStation 6, new release, RaySearch Laboratories, radiation therapy, treatment planning, TomoTherapy

February 1, 2017 — RayStation 6, the latest release of RaySearch’s radiation therapy treatment planning system, adds significant new functionality and a wide range of general improvements. Major additions include forthcoming support for Accuray TomoTherapy systems.

RaySearch said the new release sets RayStation apart as the only system to enable planning for both conventional linacs (linear accelerators) and TomoTherapy systems, giving clinics one point of control for all treatment planning needs. All contouring work can be done in one workspace. It is also possible to plan combined treatments and accurately calculate combined dose. Clinical support for TomoTherapy systems is pending final validation and will be included in a service pack to be released in the near future.

Other RayStation 6 highlights include:

  • Monte Carlo dose calculation for proton pencil-beam scanning (PBS);
  • PBS planning with block apertures;
  • Simultaneous co-optimization of multiple beamsets;
  • Magnetic resonance (MR)-based planning, using MR-image as planning image; and
  • Auto-recovery.

RayStation 6 also includes many other additions and general improvements, such as a new dose brush tool to adjust dose in user-specified regions, dose thumbnails in Plan Explorer, support for patients scanned decubitus left/right, the ability to change patient ID, improved prescribed fraction dose handling and display, as well as further enhancements to the graphical user interface (GUI).

RayStation 6 is still subject to regulatory clearance in some markets.

For more information: www.raysearchlabs.com

Related Content

targeted radiosurgery, stereotactic radiosurgery, whole-brain radiation, brain tumor metastases, Cureus, University of Missouri School of Medicine study
News | Radiation Therapy | February 16, 2017
University of Missouri (MU) School of Medicine researchers compared two common postsurgical therapies for metastatic...
ASTRO guideline, bone metastases, pallliative radiation therapy, gold standard
News | Radiation Therapy | February 14, 2017
February 14, 2017 — The American Society for Radiation Oncology (ASTRO) recently published an updated clinical guidel
Accuray, Radixact treatment delivery system, TomoTherapy, Shonin approval, Japan
News | Radiation Therapy | February 13, 2017
February 13, 2017 — Accuray Inc.
state of the proton therapy market entering 2017, proton therapy, radiation therapy, Robust Insight survey
News | Proton Therapy | February 10, 2017
Independent market research consultancy Robust Insight recently conveyed a survey commissioned by IBA on the state of...
EGFR mutant lung cancer, brain metastases, order of treatment, radiation therapy, EGFR-directed drugs, Journal of Clinical Oncology study
News | Lung Cancer | February 09, 2017
February 9, 2017 — A study published in the...
IBA, Dolphin Online Ready Patient QA and Monitoring solution, radiotherapy, North West Cancer Centre, Londonderry, Northern Ireland, first in U.K.
News | Radiation Therapy | February 07, 2017
IBA (Ion Beam Applications S.A.) recently announced the first clinical implementation of its Dolphin Online Ready...
Institut Curie, Onxeo, radiotherapy, immunotherapy, DNA repair inhibitors, AsiDNA, DBait
News | Radiation Therapy | February 06, 2017
Onxeo S.A. and the Institut Curie launched a series of studies on World Cancer Day (Feb. 4) aimed at investigating the...
radiotargeted therapy, SST2 antagonists, combat cancer, neuroendocrine tumors, NETs, Journal of Nuclear Medicine study

Comparative receptor autoradiography in various cancer types (A = HE staining) with I-125-JR11 (B+C) and I-125-Tyr3-octreotide (D+E). B and D are the respective total binding, C and E the respective non-specific binding. Bars = 1 mm.

I: Breast cancer. II: Renal cell cancer. III: Medullary thyroid cancer. IV: Non-Hodgkin lymphoma. V: Colon cancer. In cancers I-V, the sections were incubated with 30’000 cpm/100 μl of antagonist or agonist. Cancers I-IV show a much higher density of sst2 with the antagonist. The colon cancer V is negative. VI: Ileal NET, incubated with 10’000 cpm/100 μl of antagonist or agonist. Credit: Jean Claude Reubi, Institute of Pathology, University of Berne, Berne, Switzerland. 

News | Radiation Therapy | February 06, 2017
A study published in the February issue of The Journal of Nuclear Medicine demonstrates the potential of extending...
recurrent prostate cancer, hormone therapy, radiation therapy, Cedars-Sinai study, New England Journal of Medicine
News | Prostate Cancer | February 03, 2017
Adding hormonal therapy to radiation treatment can significantly improve the average long-term survival of men with...
Overlay Init